Clinical Features, Treatment, and Outcomes of Sintilimab-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Zhaoquan Wu, Yong Pan, Miao Liu, Wei Sun, Chunjiang Wang

Open source

DOI
10.1097/cji.0000000000000622
Published
2026-09-21
Container
Journal of Immunotherapy
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/cji.0000000000000622,
  title = {Clinical Features, Treatment, and Outcomes of Sintilimab-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis},
  author = {Zhaoquan Wu and Yong Pan and Miao Liu and Wei Sun and Chunjiang Wang},
  year = {2026},
  journal = {Journal of Immunotherapy},
  doi = {10.1097/cji.0000000000000622},
  url = {https://doi.org/10.1097/cji.0000000000000622}
}

RIS

TY  - JOUR
TI  - Clinical Features, Treatment, and Outcomes of Sintilimab-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
AU  - Zhaoquan Wu
AU  - Yong Pan
AU  - Miao Liu
AU  - Wei Sun
AU  - Chunjiang Wang
PY  - 2026
JO  - Journal of Immunotherapy
DO  - 10.1097/cji.0000000000000622
UR  - https://doi.org/10.1097/cji.0000000000000622
ER  - 

APA

Wu, Z., Pan, Y., Liu, M., Sun, W., & Wang, C. (2026). Clinical Features, Treatment, and Outcomes of Sintilimab-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Journal of Immunotherapy. https://doi.org/10.1097/cji.0000000000000622

Source records